Vivendy Therapeutics Ltd.

Vivendy Therapeutics Ltd. (Vivendy) is a privately held bio-pharmaceutical start up company, engaged in offering clinical research and contract research services. Currently, the company is involved in developing an enzyme replacement therapy (ERT) for morbus morquio (Mucopolysaccharidosis (MPS IVA), a rare lysosomal storage disease (LSD). Its main research focus is to identify a recombinant protein which can improve enzyme activity, there by enhancing the efficacy of the therapy in MPS IVA. Vivendy Therapeutics holds a world wide licence on IP containing a pharmaceutical composition, a fusion protein and own IP on enhancing enzyme activity. The company is headquartered in Basel, Switzerland.

Street: 
Peter Merian-Str. 45
City: 
Basel
Postcode: 
4052
Federal State : 
Switzerland
WebSite: 
www.vivendy.ch
Fax: 
41-61-2718781

Company Index Score

Current Index Score Historical Index Score
  • Vivendy Therapeutics Ltd. currently scores 50 % in the index.
  • Vivendy Therapeutics Ltd. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Vivendy Therapeutics Ltd. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets